A potential anticancer drug clioquinol inhibits mTOR activity by disrupting the integrity of mTORC1 in multiple myeloma (MM)6, a fatal malignancy of plasma cells that leads to multiple organ dysfunction and universal death. The gene discussed is MTOR; the disease is Miyoshi myopathy.